Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Frost & Sullivan Commends Altea Therapeutics for Extending Frontiers of Transdermal Drug Delivery - A new breakthrough technology that enables painless delivery through the skin of drugs that until now were administered only by needle injection, including water-soluble drugs, proteins, nucleic acids and carbohydrates
Frost & Sullivan Commends Altea Therapeutics for Extending Frontiers of Transdermal Drug Delivery

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2007/04/03 - A new breakthrough technology that enables painless delivery through the skin of drugs that until now were administered only by needle injection, including water-soluble drugs, proteins, nucleic acids and carbohydrates.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frost & Sullivan has presented Atlanta-based Altea Therapeutics with the 2007 Frost & Sullivan Technology Innovation Award in the field of transdermal drug delivery for its development of the PassPort™ System.

The PassPort System has dramatically extended the range of diseases that can be treated using transdermal patches. This novel technology has presented a great opportunity for the Company in addressing significant medical needs using a method of drug administration proven to lead to high patient compliance.

"The Altea Therapeutics PassPort System redefines the scope of transdermal delivery by enabling a cost-effective, non-invasive, and controllable way to deliver a wide range of drugs via the skin," says Frost & Sullivan Research Analyst Bhuvaneashwar Subramanian. "As the solution that finally delivers on the promise of delivery through the skin, the new PassPort System makes more patient-friendly treatments possible for a number of different conditions."

Although transdermal patches were introduced two decades ago in response to increasing demand for a more comfortable delivery system than needle injections, they are restricted to a limited number of molecules that can be delivered through the skin. Typically, the skin only allows the penetration of lipid-soluble drugs that have a molecular weight of less than approximately 500 daltons.

Various modes of transdermal drug delivery such as iontophoresis, ultrasound, microneedles, and dermabrasion have endeavored to meet the need for a more convenient form of administering larger molecules. However, these approaches have limitations relating to efficiency and reproducibility. The PassPort System has been able to overcome these challenges.

Comprising a PassPort Patch and a reusable Applicator, the technology itself is surprisingly simple to use. The patient clips the patch onto the Applicator, places it against the skin, and presses an activation button. Then, as the patient takes the Applicator away from the skin, the transdermal patch is automatically positioned on the skin to allow delivery to commence.The Applicator can also be configured to record valuable information about patient dosing, including the date and time when the transdermal patch was applied to the skin. The physician can use this information to verify patient compliance and provide proper disease management. Other value-added attributes include the ability to equip the Applicator with dose reminder and dose lockout features to prevent drug overdosing, misuse and even abuse.

"With its superior functionality and innovative features, the Passport System can potentially be employed for an extensive array of applications ranging from delivering small water-soluble molecules such as apomorphine hydrochloride to treat Parkinson’s disease to proteins such as insulin for diabetes management," says Subramanian. "It can also be used for macromolecules such as parathyroid hormone to treat osteoporosis as well as vaccines for disease prevention."

Each year Frost & Sullivan presents this Award to a company that has carried out new research, which has resulted in noteworthy innovations. These innovations have or are expected to significantly contribute to the industry in terms of adoption, change, and competitive positioning. This award recognizes the quality and depth of a company’s research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Altea Therapeutics

Altea Therapeutics (alteatherapeutics.com) is an emerging specialty pharmaceutical company developing and commercializing products based on a new transdermal patch technology that can deliver sustained therapeutic levels of highly water-soluble drugs, carbohydrates, nucleic acids, peptides and proteins through the skin in a convenient, painless, and cost-effective manner. Altea Therapeutics has demonstrated in several clinical studies that its patented PassPort Transdermal System achieves what existing patches are unable to do, namely the continuous delivery through the skin of compounds that are typically administered by needle injections.

The company is conducting several clinical trials in the United States for its products, including for an insulin transdermal patch that provides continuous delivery of basal levels of insulin for people with diabetes, a fentanyl citrate transdermal patch that enables rapid and safe management of moderate to severe pain, and an apomorphine hydrochloride transdermal patch for the convenient management of advanced Parkinson’s disease. Furthermore, the company is in pre-clinical development with a number of product candidates, including a low-molecular-weight heparin patch for thromboses, a parathyroid hormone analog transdermal patch for osteoporosis, and an atypical antipsychotic transdermal patch for the management of psychoses.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Commends Altea Therapeutics for Extending Frontiers of Transdermal Drug Delivery

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Stacie Jones 
210.247.2450 Stacie.jones[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom

Visit  JobsWare.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today